Corporate Overview of Boston Biomedical Inc. (BBI)

01.06.2009

	Company Culture
	Management Team
	Publications
	Newsroom
	Career Opportunities
	Contact Us
	Home

Boston Biomedical, Inc., was founded by Dr. Chiang J. Li and core members of ArQule, Inc.'s former R&D Biology Department in January 2007. This highly-productive and innovative R&D team started in 2002 at Cyclis Pharmaceuticals and subsequently was acquired by ArQule in 2003. Since inception, Dr. Li and his team have established extraordinary track records of accomplishments:

	Activated Checkpoint Therapy (ACT^SM)
	ARQ 501, the first ACT^SM-based small molecule that selectively kills cancer cells through E2F1-mediated DNA damage checkpoint pathway

	Activated Checkpoint Therapy (ACT^SM)
	ARQ 501 (E2F Program) was partnered with Roche in a deal valued at $276 million and is currently in multiple Phase 2 clinical trials

ARQ 197, a non-ATP competitive selective c-Met inhibitor

ARQ 197 IND was filed in November, 2005

ARQ 197 entered Phase 1 clinical trials in 2006 and is schedule to begin Phase 2 trials in 2007

The Asian market of ARQ 197 has been licensed by Kyowa Hakko Kogyo in a deal valued at $123 million with $30 M upfront licensing payment. Read more.

The phase 1 trial data released on the 2007 ASCO Annual Meeting demonstrate safety and expanded anti-cancer activity. Read more.

ARQ 171, a second generation ACT^SM-based E2F1 pathway activator.

	ARQ 171 IND was filed in October, 2006
	ARQ 171 initiated Phase 1 clinical trials in December, 2006

ARQ 450RP, a clinical candidate selection stage program on mitotic checkpoint activators

Discovery stage programs, including ArQ800RP - checkpoint activators, ArQ300RP - Eg5 inhibitors, and ArQ850RP - p53 Modulators

Based upon the strength of its researchers, Boston Biomedical, Inc. will continue to leverage scientific excellence and leadership to ensure a successful future.

|||||||